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Background/aims: Methodological challenges have been associated with the dynamic measurement of
muscle protein breakdown (MPB), as have the measurement of both muscle protein synthesis (MPS) and
MPB within the same experiment. Our aim was to use the transmethylation properties of methionine as
proof-of-concept to measure rates of MPB via its methylation of histidine within skeletal muscle
myoﬁbrillar proteins, whilst simultaneously utilising methionine incorporation into bound protein to
measure MPS.
Results: During the synthesis measurement period, incorporation of methyl[D3]-13C-methionine into
cellular protein in C2C12 myotubes was observed (representative of MPS), alongside an increase in the
appearance of methyl[D3]-methylhistidine into the media following methylation of histidine (repre-
sentative of MPB). For further validation of this approach, fractional synthetic rates (FSR) of muscle
protein were increased following treatment of the cells with the anabolic factors insulin-like growth
factor-1 (IGF-1) and insulin, while dexamethasone expectedly reduced MPS. Conversely, rates of MPB
were reduced with IGF-1 and insulin treatments, whereas dexamethasone accelerated MPB.
Conclusions: This is a novel stable isotope tracer approach that permits the dual assessment of muscle
cellular protein synthesis and breakdown rates, through the provision of a single methionine amino acid
tracer that could be utilised in a wide range of biological settings.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The use of stable isotope labelled compounds in musculoskel-
etal research, through dynamic measurement of rates of meta-
bolism and turnover of proteins across a range of conditions and
interventions, has allowed us to gain crucial insights into fuel and
protein metabolism in health and disease [1,2]. Studying protein
turnover and its relation to the regulation of muscle mass in terms
of both hypertrophy (muscle growth) and atrophy (muscle loss) is
of key importance for understanding the regulation of metabolic
health and the role of skeletal muscle in health and disease. For
measurement of muscle protein synthesis (MPS) using stable
isotope tracers, these techniques have been extensively developed
over the years, from the use of direct incorporation measures, usingculoskeletal Ageing Research,
Research Centre, School of
, UK.
.J. Wilkinson).
r Inc. This is an open access articleprecursor-product methods, to the use of arterio-venous (A-V)
balance across a tissue bed [1].
However, method development for the measurement of muscle
protein breakdown (MPB) has been associated with greater chal-
lenges, due to the complex nature of the study design employed
(multiple tracer boluses or constant infusions), the complex
mathematical assumptions required, as well as the assumption that
there is minimal recycling of the amino acid (AA) tracer back into
bound protein pool [3,4]. Hence, the relative paucity of information
relating to control of protein breakdown in physiological systems
and conditions. One primary method for assessing dynamic MPB
involves infusion/incubation of a stable isotope labelled amino acid
and measuring its rate of appearance (via dilution of the tracer)
from tissues or cells [5,6]. These models have provided important
physiological insights into musculoskeletal protein metabolism,
although there are certain limitations associated with the tech-
nique, such as the assumption of steady state, and underestimation
of MPB due to the possibility of reutilization of amino acids for MPS
[7].
Another approach to assess MPB involves measurement of 3-under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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dine found in myoﬁbrillar proteins. Once released from the peptide
during protein breakdown, methylhistidine cannot be reincorpo-
rated into proteins, and is excreted from the body in the urine. The
urinary excretion of methylhistidine has been frequently used as a
proxy measure of whole body and skeletal muscle protein break-
down [8,9], although there has been debate as to how accurately
this reﬂects muscle as methylhistidine can be formed in other
proteins in the body i.e. the gut [10] (although the majority is
believed to be contained in actin and myosin ﬁlaments [11]).
The aim of the present study was to develop a novel stable
isotope tracer approach that overcomes some the issues associated
with current protein breakdown measures, and was able to mea-
sure MPS and MPB within the same experiment utilising a single
isotopically labelled amino acid tracer. Using methyl[D3]-13C-
methionine, we have developed this proof-of-concept method,
utilisingmurine C2C12myotubes in vitro, performing a time-course
study for both MPS and MPB. We measured the incorporation of
methyl[D3]-13C-methionine into protein to determine protein
synthesis and measured the rate of appearance of methyl[D3]-his-
tidine, following the transfer of the tri-deuterated methyl group of
methyl[D3]-13C-methionine, via [methyl-D3]-S-adenosyl-13C-
methionine onto histidine residues in myosin and actin, as a
measure of proteolysis of myoﬁbrillar proteins. Furthermore, we
have validated the approach using interventions that are known to
either positively (IGF-1/insulin) and/or negatively (Dexametha-
sone) regulate MPS and MPB.
2. Materials and methods
2.1. C2C12 cell culture
Murine C2C12 cells (ECASS, Salisbury, UK) were maintained in
Dulbecco’s Modiﬁed Eagle Medium (DMEM; Thermo Fisher Scien-
tiﬁc) containing 10% (v/v) fetal bovine serum (FBS), 1% (v/v)
antibiotic-antimycotic solution and 4 mM L-glutamine (all from
Sigma-Aldrich, UK) and kept in a 37 C incubator with 5% CO2.
Myoblasts were seeded onto collagen-coated (Type I from rat tail;
Sigma-Aldrich, UK) six-well multidishes (Nunclon™ Delta; Thermo
Fisher Scientiﬁc) and when conﬂuency reached ~90%, differentia-
tion was induced by changing to DMEM containing 2% (v/v) horse
serum, 1% (v/v) antibiotic-antimycotic solution and 4 mM L-gluta-
mine (Sigma-Aldrich, UK). The media was changed every 48 h and
experiments were performed on days 4e5 post-switch to differ-
entiation media.
2.2. Methyl[D3]-
13C-methionine tracer experiments
The theory behind the technique relates to the transmethylation
properties provided by the essential AA methionine. Following
conversion to S-adenosylmethionine (SAMe) by methionine ade-
nosyltransferase, this compound can act as a methyl donor for a
number of compounds [12,13], including the post-translational
modiﬁcation of histidine residues to methylhistidine following
peptide formation, principally in actin and myosin in muscle [13].
The method developed in the present study is based on the
theory that provision of methyl[D3]-13C-methionine will primarily
act as substrate for MPS within the cell; however also that a pro-
portion of the methionine will act as a methyl donor, transferring
the methyl[D3] group to other compounds, including histidine in
the bound protein (see Fig. 1). Following MPB, this methyl[D3]-
methylhistidinewill be released and its rate of cellular/extracellular
accumulation will be representative of the rate of MPB. Moreover,
through the addition of the 13C label, the methyl[D3]-13C-methio-
nine that is not utilised as a methyl donor (and potentially thatwhich is too, as homocysteine can be methylated back to methio-
nine via folate intermediates) will be incorporated into new pro-
tein, meaning that we can monitor the rate of cellular protein
synthesis by measuring the rate of incorporation of this D3 13C-
methionine into protein. Similarly, we could have utilised a
methionine tracer, containing only a deuterated Methyl moiety.
Initial experiments aimed to assess the time course of methyl
[D3]-13C-methionine incorporation into cellular protein, and the
subsequent disappearance from cells (and appearance in media) in
the form of D3-3-methylhistidine. For MPS measures, methyl
[D3]-13C-methionine was added into the media (to achieve an
enrichment of ~15 atom percent excess (APE)) at the point of the
media change on day 4 post differentiation. Cells were incubated
for 4, 6, 8, 24 and 48 h, after which the media was collected, and
cells were harvested in 0.2 mol L-1 perchloric acid (PCA) for GC-MS
analysis (see below). For MPB measures, cells were incubated with
methyl[D3]-13C-methionine (as above) for 24 h, after which cells
were washed with Hank’s balanced salt solution (HBSS) and fresh
media (without tracer) replaced. Cells and media were collected
after 4, 6, 8, 24 and 48 h. All experiments were repeated twice and
performed using n ¼ 4e6 well replicates each time.
For determining whether the method can quantiﬁably detect
differences in MPS and MPB under different conditions, cells were
incubated with selected compounds known to inﬂuence MPS and/
or MPB (insulin-like growth factor 1 (IGF-1), 50 ng/ml; insulin,
300 nmol L-1, and dexamethasone (Dex), 1 mmol L-1). For MPS
measures, treatments were added at the same time as the tracer,
whereas for MPB, treatments were added following the addition of
tracer-free media after an incubation period with the tracer. In both
cases, samples were harvested after 24 h or 48 h treatment. For
measuring protein markers of MPS/MPB following each treatment,
cells were harvested in homogenisation buffer (50 mmol L-1 Tris-
HCl, pH 7.5, 1 mmol L-1 EDTA, 1 mmol L-1 EGTA, 10 mmol L-1
ß-glycerophosphate, 50 mmol L-1 NaF and complete protease in-
hibitor cocktail tablet (Roche, West Sussex, UK)) for Western blot
analysis (see below).
2.3. GC-MS analysis of methyl[D3]-
13C-methionine
Harvested cells were centrifuged (10,000 rpm, 10 min) and the
pellet was washed twice with 70% (v/v) ethanol. The pellet was
then hydrolysed overnight at 100 C in 1 ml of HCl (0.1 mol L-1)
with 1 ml Hþ dowex resin in ddW. Hydrolysed AAwere isolated by
passing through dowex columns, eluted into 2 mol L-1 NH4OH and
dried down. Labelling (13C/D3) of protein-bound methionine was
determined using GC-MS following MTBSTFA derivatization and
single ion monitoring (SIM) of m/z 320, 324. Media samples from
each well were also puriﬁed via dowex columns and dried down
and derivatized in the sameway as for the cells. Fractional synthesis
rate (FSR) was calculated using the following equation:
FSR (%/h) ¼ -ln(1-(APEproduct/APEprecursor)/t)100
where APEproduct ¼ the change in protein-bound enrichment of
methyl[D3]-13C-methionine, APEprecursor ¼ the average in
enrichment of methyl[D3]-13C-methionine in the media and
t ¼ time in hours.
2.4. LC-MS analysis of methyl[D3]-3-methylhistidine
Cell and media samples were processed in the same manner as
for MPS measures to the point of being dried down after elution
from dowex columns. Labelling of methyl-D3-3-methylhistidine
was performed using HILIC phase liquid chromatography coupled
to ESI-high resolution mass spectrometry (Q-Exactive, Thermo
Fig. 1. Schematic representing proposed mechanism of action of [methyl-D3]-13C-methionine tracer. Methyl[D3]-13C-methionine will primarily act as substrate for muscle
protein synthesis (MPS) within the cell, however a proportion of the methionine will act as a methyl donor, transferring the methyl[D3] group to other compounds, including
histidine in the bound protein. Following muscle protein breakdown (MPB), methyl[D3]-methylhistidine will be released and its rate of cellular/extracellular accumulation will be
representative of the rate of MPB.
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(SIM) of m/z 170.09230, 173.11131 for 3-MH and D3-3 MH
respectively.
Fractional breakdown rate (FBR) was calculated using the
following equation:
FBR (%/h) ¼ -ln(1-(APEprecursor/APEproduct)/t)100
where APEproduct ¼ the change in protein-bound enrichment of
methyl[D3]-3-methylhistidine, APEprecursor ¼ the change in
enrichment of methyl[D3]-3-methylhistidine in the media and
t ¼ time in hours.2.5. Western blot analysis
Cell samples were lysed by repeatedly passing through gel-
loading pipette tips. Lysates were centrifuged (13,000 g, 10 min,
4 C) and protein (10 mg) was loaded onto Criterion XT 12% gels
(Bio-Rad, UK) for electrophoresis at 200 V for 1 h. Proteins were
transferred to PDVF membranes (100 V, 45 min), then membranes
were blocked in 5% (w/v) milk for 1 h at room temperature. Primary
antibody incubations (p70 S6K1 Thr389, 1:2000; AKT Ser473,
1:2000; eEF2 Thr56, 1:2000; LC3B, 1:2000; and MAFbx, 1:2000; all
primary antibodies were purchased from Cell Signaling) were
performed overnight at 4 C, after which membranes were washed
for 3  5 min using 1x Tris-buffered saline (TBS)-Tween then
incubated in HRP-conjugated anti-rabbit secondary antibody
(1:2000 dilution) for 1 h at room temperature. Membranes were
subsequently washed a further 3 5min in TBS-Tween, then bands
were detected using Chemiluminescent HRP Substrate (Millipore
EMD) on a Chemidoc XRS imaging system (Bio-Rad, UK). Intensity
of bands were normalised against total protein loading through
Coomassie staining of the membrane.2.6. Statistical analysis
Data are presented as mean þ SEM and analysed using Graph-
Pad Prism version 7 (La Jolla, USA). For comparing differences be-
tween treatments and untreated controls, one-way ANOVA was
used, with correction for multiple comparisons using Sidak’s test,
with P < 0.05 taken as statistically signiﬁcant3. Results
3.1. Time course of methyl[D3]-
13C-methionine incorporation and
methyl[D3]-3-methylhistidine appearance from cells
Incorporation of methyl[D3]-13C-methionine into protein in
C2C12 myotubes was observed over time in a non-linear manner
(Fig. 2A), and by 48 h had reached an enrichment in cellular protein
of 8.5 ± 0.1%. MPS rates were higher at 6 h post addition of the
tracer (with media change) relative to at 4 h (2.2 ± 0.1%/h at 4 h;
2.6± 0.1%/h at 6 h; P< 0.05 vs. 4 h), and gradually declining over the
next 24 h and by 48 h were lower to that of 4 h (1.4 ± 0.01%/h at
48 h; P < 0.001 vs. 4 h; Fig. 2B).
During initial development of the method, we were unable to
detect the generation of a fragment containing the 13C mass only
(mþ1) via GC-MS, therefore FSR calculations were made using the
enrichment from the 13C and [D3]-containing (mþ4) compound. It
is possible that use of an alternative derivative could generate a
fragment containing the 13C solely, however similar rates for FSR
were observed using the masses chosen.
LC-MS analysis of methyl[D3]-3-methylhistidine showed that
following an initial incubation period with methyl[D3]-13C-methi-
onine (and subsequent removal from the media), there was an in-
crease in the appearance of methyl[D3]-3-methylhistidine into the
cell culture media over time (Fig. 2C), while cellular bound methyl
[D3]-methylhistidine enrichment decreased. Calculations of FBR
Fig. 2. Time course of [methyl-D3]-13C-methionine incorporation and cellular release of [methyl-D3]-methylhistidine in C2C12 myotubes. C2C12 myotubes were incubated for
various times with [methyl-D3]-13C-methionine. A & B, changes in enrichment of protein-bound methionine over time, and fractional synthetic rate (FSR) in %/h over time. C & D,
changes in enrichment of media [methyl-D3]-methylhistidine over time, and fractional breakdown rate (FBR) in %/h over time. E, net balance across time, expressed as %/h. Data are
mean ± SEM, n ¼ 4 well replicates for each time point. *; P < 0.05, ***; P < 0.001 vs. 4 h.
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(between 4 h (2.3 ± 0.3%/h) and 8 h (2.2 ± 0.2%/h)), and increased
by 48 h (4.8 ± 0.2%/h; P < 0.001 vs. 4 h) post media change (Fig. 2D).
Net balance (calculated as MPS - MPB) across the time course
remained close to zero (Fig. 2E), but was signiﬁcantly decreased by
48 h post media change (P < 0.001 vs. 4 h).3.2. Effect of selected treatments on methyl[D3]-
13C-methionine
incorporation and methyl[D3]-3-methylhistidine appearance from
cells
A 24 h and 48 h period of selected treatments known to inﬂu-
ence MPS and/or MPB was undertaken to test the validity of the
tracer. Over 24 h, IGF-1 caused a signiﬁcant increase in MPS
(2.2 ± 0.03%/h vs. 1.9 ± 0.1%/h; P < 0.05; Fig. 3A) and was still
elevated above control by 48 h. Equally, IGF-1 suppressed MPB at
48 h (2.3 ± 0.3%/h vs. 3.7 ± 0.3%/h; P < 0.05 vs. control; Fig. 3B).
With insulin treatment, the FSR of muscle protein was elevated at
24 h (2.3 ± 0.03%/h; P < 0.01; Fig. 3A) compared to control, while at
48 h it was not signiﬁcantly different from control (Fig. 3A). As
expected, there was a marked decrease in MPB at both 24 h and
48 h (1.4 ± 0.4%/h vs. 2.8 ± 0.1%/h at 24 h; P < 0.01 vs. control;
1.6 ± 0.1%/h vs. 3.7 ± 0.3%/h at 48 h; P < 0.001 vs. control; Fig. 3B).
Finally, treatment with the catabolic agent Dex resulted in a sig-
niﬁcant suppression of MPS at 48 h only (1.3 ± 0.1%/h vs.
1.5 ± 0.03%/h; P < 0.05 vs. control; Fig. 3A) as well as increases in
MPB (5.2 ± 0.4%/h vs. 3.7 ± 0.3%/h; P < 0.05 vs. control; Fig. 3B). Net
balance was therefore signiﬁcantly higher with both insulin and
IGF-1 treatments relative to untreated cells (Fig. 3C), and lower
than control following 48 h Dex treatment (Fig. 3C; P < 0.01 vs.
control). These treatments provide proof-of-concept validation that
our tracer approach is sensitive to measure changes in both MPB
and MPS.3.3. Effect of selected treatments on total protein content and
markers of MPS/MPB
Total protein content and selected protein markers of MPS and/
or MPB were measured to further verify the effects of each treat-
ment. Total protein content per well was increased following 24 h
IGF-1 and insulin treatments (613 ± 21 mg and 590±8 mg versus
460±5 mg; both P < 0.001 vs. control), while protein was decreased
after Dex treatment (425±5 mg; P < 0.05 vs. control; Fig. 4A).
Phosphorylated p70 S6K1 was signiﬁcantly elevated by both
IGF-1 (1.5 ± 0.08-fold; P < 0.001 vs. control) and insulin (1.8 ± 0.07-
fold; P < 0.001 vs. control) treatments, indicating activation of
p70S6K1 activity, whereas Dex caused a reduction in p70 S6K1
Thr389 (0.75 ± 0.09-fold; P < 0.05 vs. control; Fig. 4B). Similarly,
phosphorylated AKT (Ser473) was signiﬁcantly increased by both
IGF-1 (3.4 ± 0.07-fold; P < 0.001 vs. control) and insulin (2.9 ± 0.07-
fold; P < 0.001 vs. control) treatments (which is indicative of AKT
activation), whereas Dex caused a reduction in phosphorylated AKT
(0.75 ± 0.09-fold; P < 0.05 vs. control; Fig. 4C). Following both 24 h
IGF-1 and insulin incubations, phosphorylated eEF2 (Thr56) was
signiﬁcantly decreased (consistent with increased translation
elongation) (0.57 ± 0.02-fold; P < 0.001 vs. control and 0.66 ± 0.03-
fold; P < 0.001 vs. control, respectively; Fig. 4D), while eEF2 Thr56
phosphorylation was increased with Dex (1.3 ± 0.04-fold; P < 0.01
vs. control).
The ratio of LC3-II to LC3-I protein was unaltered with IGF-1
treatment, but was signiﬁcantly decreased with insulin
(0.8 ± 0.04-fold; P < 0.05 vs. control; Fig. 4E), while following Dex
treatment, the ratio of LC3-II to LC3-I protein was increased
(1.4 ± 0.1-fold; P < 0.05 vs. control). Following 24 h IGF-1 incuba-
tion, MAFbx protein was unchanged, but with insulin MAFbx pro-
teinwas signiﬁcantly decreased (0.6 ± 0.1-fold; P < 0.05 vs. control;
Fig. 4F), while total MAFbx was increased with Dex (1.8 ± 0.2-fold;
P < 0.01 vs. control).
Fig. 3. Effect of selected treatments on [methyl-D3]-13C-methionine incorporation and cellular release of [methyl-D3]-methylhistidine in C2C12 myotubes. C2C12 myotubes
were incubated for 24 h or 48 h with [methyl-D3]-13C-methionine, and treated with insulin-like growth factor 1 (IGF-1; 50 ng/ml), insulin (300 nmol L1) or dexamethasone (Dex;
1 mmol L1). In breakdown experiments, treatments were added following removal of the tracer after an initial 24 h incubation period. A, changes in fractional synthetic rate (FSR)
following IGF-1, insulin or Dex treatments. B, changes in fractional breakdown rate (FBR) following IGF-1, insulin or Dex treatments. C, net balance (%/h) following IGF-1, insulin or
Dex treatments. Data are mean ± SEM, n ¼ 6 well replicates for each group. *; P < 0.05, **; P < 0.01, ***; P < 0.001 vs. control.
Fig. 4. Effect of selected treatments on total protein and anabolic/catabolic signaling in C2C12 myotubes. C2C12 myotubes were treated for 24 h with insulin-like growth factor
1 (IGF-1; 50 ng/ml), insulin (300 nmol L-1) or dexamethasone (Dex; 1 mmol L-1). A, total protein per well following IGF-1, insulin or Dex treatments. BeF, changes in phosphorylated
p70 S6K1 (Thr389), phosphorylated AKT (Ser473), phosphorylated eEF2 (Thr56), ratio of LC3-II/I and total MAFbx protein following IGF-1, insulin or Dex treatments. Data are
mean ± SEM, n ¼ 6 well replicates for each group. *; P < 0.05, **; P < 0.01, ***; P < 0.001 vs. control.
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While many crucial insights into skeletal muscle protein ho-
meostasis with health and during catabolic conditions such ascachexia and sarcopenia have been gained with the use of stable
isotope tracers [14e16], methodological challenges with the mea-
surement of MPB have been faced [7,17]. In this proof-of-concept
study, our aim was to use the transmethylation properties of
H. Crossland et al. / Metabolism Open 5 (2020) 1000226methionine to measure MPB through the methylation of histidine
within bound muscle proteins and its subsequent release as
labelled methyl[D3]-3-methylhistidine, whilst also utilising
methionine incorporation into bound protein to measure MPS
simultaneously. Wewere able to demonstrate that the dual labelled
tracer methyl[D3]-13C-methionine could be used to both accurately
assess MPS rates in muscle cells in vitro, whilst also being used to
quantify MPB through LC-MS analysis of methyl[D3]-3-
methylhistidine release from cellular proteolysis into the media.
This provides the ﬁrst stable isotope tracer technique that can
measure both muscle protein synthesis and myoﬁbrillar break-
down rates through the simple provision of a single amino acid
tracer.
Development of the use of methyl[D3]-13C-methionine as a
suitable tracer for assessing MPS was achieved by monitoring its
incorporation into cellular protein over time (Fig. 2). There was (as
expected) a non-linear increase in cellular enrichment of the tracer,
with relatively steady rates of MPS over the 48 h period and the
highest rates of MPS at 6 h post-media change. The reason for the
relative decrease in net balance at 48 h could reﬂect cellular re-
sponses to the media change in terms of substrate depletion (i.e. a
relative increase in MPB and decrease in MPS). Nevertheless, these
ﬁndings indicated that this tracer could be used to accurately es-
timate MPS in vitro similar to our previously established ap-
proaches such as 13C proline, and D2O [18,19].
Current techniques used to measure MPB includes analysis of 3-
MH, a post-translationally methylated form of histidine that arises
from degradation of actin and myosin. Measurement of 3-MH can
be used to measuremyoﬁbrillar proteolysis and thus estimate MPB,
since once formed it cannot be further metabolized nor reincor-
porated into protein [8,9]. In addition, measuring the rate of release
of a labelled amino acid from cells represents an alternativemethod
used to quantify MPB. This involves initial incubation with a
labelled form of an amino acid that cannot be synthesized or
metabolized by muscle (e.g. tyrosine), therefore its release from
cellular protein can be used to assess rates of MPB [5]. However,
certain problems can arise if labelled amino acids released during
MPB are recycled back into cellular protein, which can result in
substantial underestimation of MPB rates. Our approach was to test
the hypothesis that the methyl[D3] group from methyl[D3]-13C-
methionine would be transferred to other compounds, including
the histidine residues within bound protein. This would allow us to
measure the appearance and rate of release of methyl[D3]-meth-
ylhistidine followingmuscle proteolysis. A time course following an
initial incubation period with the tracer, and subsequent removal,
demonstrated non-linear increases in methyl[D3]-methylhistidine
appearance in the media, as well as a decay in enrichment from the
bound protein pool. In terms of MPB, rates were relatively consis-
tent across time for the initial 24 h post-media change (Fig. 2D),
with increases by 48 h. Thus, addition of the methyl[D3]-13C-
methionine tracer provides a novel approach to quantify MPB,
through a direct transfer of the methyl[D3] group to protein-bound
histidine. Moreover, this technique overcomes a major limitation of
other MPB tracer techniques in terms of the assumptions made in
relation to amino acid recycling from proteolysis, as the methyl-
histidine is not re-incorporated back into protein, nor further
metabolized within the muscle cells.
Having established that the tracer could accurately be used to
measure both MPS and MPB rates in vitro, further validity for the
method was achieved using compounds known to modulate MPS
and/or MPB. Both IGF-1 and insulin have both been known to
induce anabolic as well as anti-catabolic changes in skeletal muscle
cells [20e22], while Dex both inhibits MPS and accelerates catab-
olism in C2C12 cells [23,24]. The increase in MPS with insulin and
IGF-1, and the reduction in MPS with Dex therefore, wereconsistent with previously reported changes with these treat-
ments, further supporting the use of this tracer as a robust
approach for estimating muscle FSR. Accretion of total protein
content (Fig. 4A), as well as activation of key anabolic proteins (p70
S6K1, AKT, eEF2) following 24 h IGF-1 and insulin treatments were
also indicative of net increases in MPS and decreases in MPB,
adding further support for the effects of each treatment.
As with the MPS measures, measuring speciﬁc markers of MPB
further veriﬁed the effects of each treatment. Dex has previously
been shown to upregulate muscle atrophy F-box (MAFbx) and
muscle RING ﬁnger 1 (MuRF1), in linewith its established effects on
activation of ubiquitin-proteasome pathway (UPP)-mediated pro-
teolysis [25,26]. Conversely, both IGF-1 and insulin treatments have
been linked to downregulation of expression of UPP markers
MAFbx and MuRF1, at least at the gene level [20,21,27]. Observed
decreases in total protein in the present study, as well as decreased
activation of anabolic signaling pathways (p70 S6K1, AKT, eEF2),
were therefore in linewith the expected inhibitory effects of Dex on
MPS. In addition, activation of the autophagy marker LC3 (the ratio
of LC3-II to LC3-I being a commonly usedmarker of autophagy [28])
and increased MAFbx protein with Dex (and decrease with insulin
treatment), largely conﬁrmed that the treatments were effectively
inﬂuencing MPB. Thus, the changes in rates of MPB observed
following each treatment, i.e. consistent decreases in MPB with
chronic IGF-1 and insulin, but elevated MPB following 48 h Dex
treatment, are entirely in line with previous studies as described
above. These ﬁndings provide further support that our method can
accurately and reliably be used to quantify changes in myoﬁbrillar
MPB in response to known anabolic and catabolic factors. The fact
that we were able to detect quantiﬁable changes in both MPS and
MPB across a range of anabolic/catabolic conditions highlights the
potential of this novel tracer approach in contributing to our un-
derstanding of muscle protein turnover in a wide range of physi-
ological conditions in both cell and pre-clinical models.
In conclusion, in the present study we aimed to overcome some
methodological challenges associated with measuring the rates of
MPS and MPB within the same experiment, by developing a novel
stable isotope technique that utilizes a single multiply labelled
amino acid that has the capacity to measure both MPS and MPB
within the same experiment. Wewere able to demonstrate that the
tracer methyl[D3]-13C-methionine could be used for accurately
measuring MPS and MPB in a skeletal muscle cell model in vitro,
using selected treatments previously known to alter MPS and/or
MPB to validate the method. We anticipate that with further vali-
dation and development this method could be widely used and
adapted for a range of physiological settings within the ﬁeld of
musculoskeletal research (particularly in in vivo pre-clinical models
and potentially in human metabolic research) as well as other
disciplines, though this technique may be less suitable for those
tissues with lowconcentrations of actin andmyosin. Nonetheless, it
is likely that the underpinning theoretical frameworks would be
similar across cell types. Ultimately, for the many potential appli-
cations possible, the end user would need to optimise our proof-of-
concept approach in their cell type/culture systems of interest.
Other methylation events downstream of the SAMe pathway could
potentially be evaluated with adaptation of this tracer technique,
such as DNA or phospholipid methylation, or potentially other
amino acids within proteins. Further development and validation
will be required to test the potential of this tracer in other cell
types/species, particularly aiming to verify that this technique can
be applied to studying skeletal muscle protein metabolism in vivo.
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